WO2024257013 - BIOMARKERS AND METHODS FOR TREATMENT WITH NAE INHIBITORS
National phase entry is expected:
Publication Number
WO/2024/257013
Publication Date
19.12.2024
International Application No.
PCT/IB2024/055802
International Filing Date
13.06.2024
Title **
[English]
BIOMARKERS AND METHODS FOR TREATMENT WITH NAE INHIBITORS
[French]
BIOMARQUEURS ET MÉTHODES DE TRAITEMENT AVEC DES INHIBITEURS DE NAE
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
YEH, Tammie
RAMESH, Radha
Priority Data
63/508,842
16.06.2023
US
63/599,169
15.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
JPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5403 | |
| EPO | Filing, Examination, Granting | 114034 | |
| Japan | Filing, Examination, Granting | 4611 | |
| South Korea | Filing, Examination, Granting | 8635 | |
| USA | Filing, Examination, Granting | 30190 |
Total:
162,873
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are markers whose mutational status is associated with sensitivity to treatment with NAE inhibitors. Mutational status is determined by measurement of characteristics of markers corresponding to the marker genes. Compositions and methods are provided to assess markers of marker genes to predict response to NAE inhibition treatment.[French]
L'invention concerne des marqueurs dont l'état mutationnel est associé à la sensibilité au traitement par des inhibiteurs de NAE. L'état mutationnel est déterminé par la mesure de caractéristiques de marqueurs correspondant aux gènes marqueurs. L'invention concerne des compositions et des procédés pour évaluer des marqueurs de gènes marqueurs pour prédire une réponse à un traitement d'inhibition de NAE.